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Sex Differences in Cardiovascular 
Outcomes of Older Adults After Myocardial 
Infarction
Anne M. Kerola , MD, PhD; Antti Palomäki , MD, PhD; Päivi Rautava , MD, PhD; Maria Nuotio , MD, PhD; 
Ville Kytö , MD, PhD
BACKGROUND: Evidence on the impact of sex on prognoses after myocardial infarction (MI) among older adults is limited. We 
evaluated sex differences in long- term cardiovascular outcomes after MI in older adults.
METHODS AND RESULTS: All patients with MI ≥70 years admitted to 20 Finnish hospitals during a 10- year period and discharged 
alive were studied retrospectively using a combination of national registries (n=31 578, 51% men, mean age 79). The primary 
outcome was combined major adverse cardiovascular event within 10- year follow- up. Sex differences in baseline features 
were equalized using inverse probability weighting adjustment. Women were older, with different comorbidity profiles and 
rarer ST- segment– elevation MI and revascularization, compared with men. Adenosine diphosphate inhibitors, anticoagula-
tion, statins, and high- dose statins were more frequently used by men, and renin- angiotensin- aldosterone inhibitors and beta 
blockers by women. After balancing these differences by inverse probability weighting, the cumulative 10- year incidence of 
major adverse cardiovascular events was 67.7% in men, 62.0% in women (hazard ratio [HR], 1.17; CI, 1.13– 1.21; P<0.0001). 
New MI (37.0% in men, 33.1% in women; HR, 1.16; P<0.0001), ischemic stroke (21.1% versus 19.5%; HR, 1.10; P=0.004), and 
cardiovascular death (56.0% versus 51.1%; HR, 1.18; P<0.0001) were more frequent in men during long- term follow- up after 
MI. Sex differences in major adverse cardiovascular events were similar in subgroups of revascularized and non- revascularized 
patients, and in patients 70 to 79 and ≥80 years.
CONCLUSIONS: Older men had higher long- term risk of major adverse cardiovascular events after MI, compared with older 
women with similar baseline features and evidence- based medications. Our results highlight the importance of accounting for 
confounding factors when studying sex differences in cardiovascular outcomes.
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Despite decreasing rates of myocardial infarction (MI) during the past 50 years, MI is a major con-tributor to morbidity in both sexes, and ischemic 
heart disease remains the leading cause of death glob-
ally.1 Emerging evidence highlights sex differences in the 
pathophysiology, clinical presentation, and outcomes 
of MI.2,3 In general, women experience their first MI at 
an older age and have higher comorbidity burdens than 
men. Women are traditionally thought to present more 
often with atypical MI symptoms, although the factu-
ality of this statement has recently been questioned.4 
In addition, women may experience longer delays to 
reperfusion, lower revascularization rates, and less ac-
tive pharmacological secondary prevention.5,6 Partly 
because of these differences, many studies have 
reported higher mortality after MI among women, 
compared with men, in unadjusted analyses.7– 9 After 
adjusting for relevant confounding factors such as age, 
comorbidities, and treatment of MI, results have been 
more mixed.8– 11 Furthermore, worse prognoses after 
MI in women may be limited to hospitalization periods, 
not out- of- hospital deaths and long- term outcomes.9,12
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Older patients have long been underrepresented 
in acute coronary syndrome trials, and a paucity of 
data exists about outcomes and their determinants 
after MI in older adults.13 Older patients with acute 
coronary syndrome are more likely to present atypi-
cally, have more comorbidities, and worse outcomes 
than younger patients.14 Many studies have demon-
strated that, although short- term mortality after MI 
may be higher among younger women compared 
with younger men, this sex difference is attenuated 
with increasing age.15,16 Analyses of sex differences 
in MI outcomes focusing on older adults (≥70 years) 
are few and mostly do not support poorer progno-
ses among older women.9,16 Although many previous 
studies exploring sex differences among older adults 
have focused on short- and intermediate- term mortal-
ity after MI,15,17 evidence on long- term cardiovascular 
outcomes is limited.
Acknowledging the aforementioned gaps in 
the current knowledge, we explored sex differ-
ences in long- term cardiovascular outcomes after 
MI in older adults. We used nationwide longitudinal 
register- linkage data and addressed important con-
founders, including age, comorbidities, and type and 




From the Care Register for Health Care in Finland, we 
retrospectively collected data on all consecutive pa-
tients with MI aged ≥70 years admitted to participat-
ing hospitals in Finland between January 1, 2005 and 
December 31, 2014 and discharged alive. Participating 
hospitals comprised all MI- treating hospitals in Finland 
equipped with a coronary catherization laboratory 
(n=20, including 5 hospitals with emergency cardiac 
surgery). The index MI was defined as the first- time ad-
mission for an out- of- hospital MI during the study pe-
riod, with International Classification of Diseases, Tenth 
Revision (ICD- 10) code I21 as the primary discharge 
diagnosis. Exclusion criteria were death within 90 days 
after MI admission, admission duration >180  days, 
valvular or aortic surgery, and missing follow- up data 
(0.3% of patients) (Figure  S1). The IPW method was 
used to create sex groups with balanced baseline fea-
tures. Ward and hospital transfers were combined as 
a single admission.
The primary outcome of interest was composite 
major adverse cardiovascular event (MACE; new MI, 
ischemic stroke, or cardiovascular death). Secondary 
outcomes were cardiovascular death, new MI, and 
ischemic stroke. Outcomes were followed for 10 years, 
beginning 90 days after the index MI. In addition, we 
explored the use of evidence- based secondary pre-
ventive cardiovascular medications within 90  days 
of discharge from the index MI, including both newly 
prescribed medications as well as medications that 
were continued during the 90- day period after MI. 
Outcomes, comorbidities, and medications are de-
fined in Data S1, Tables S1 and S2.
Study Data
Data of all hospital and emergency room admis-
sions and major interventional procedures in 
Finland (Care Register for Health Care in Finland 
registry) and data on malignancies (Finnish Cancer 
Registry) were obtained from the National Institute 
for Health and Welfare of Finland (permission no: 
THL/2245/5.05.00/2019). Data on mortality were ob-
tained from Statistics Finland (permission no: TK- 53- 
484- 20). Data on prescription medication purchases 
and drug reimbursement permissions were obtained 
from the Social Insurance Institution of Finland (per-
mission no: 91/522/2015). The aforementioned regis-
tries are mandatory by law and have full coverage of 
CLINICAL PERSPECTIVE
What Is New?
• After adjusting for age, comorbidities, myo-
cardial infarction (MI) type, revascularization, 
and evidence- based medications, older men 
(≥70  years) with MI had a 17% higher 10- year 
risk of a major adverse cardiovascular event 
than women.
• These findings persisted in subgroup analyses 
among patients with MI aged 70 to 79 or ≥80 
and among revascularized and nonrevascular-
ized patients.
What Are the Clinical Implications?
• Our results highlight the importance of account-
ing for a wide range of confounding factors, in-
cluding MI type and treatment, when studying 
sex differences in cardiovascular outcomes 
after MI.
• Among older adults, female sex is not an inde-
pendent negative prognostic factor after MI, but 
long- term cardiovascular prognosis is worse 
among men.
Nonstandard Abbreviations and Acronyms
IPW inverse probability weighting
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the Finnish population.18 As our study used routinely 
recorded administrative health records, informed 
consent was not required, nor were the participants 
contacted. Like all studies utilizing only registry data, 
the study was exempt by law from institutional review 
board review. Legal grounds for the data handling 
are public interest and scientific research (European 
Union General Data Protection Regulation 2016/679, 
Article 6(1)(e) and Article 9(2)(j); Data Protection Act, 
Sections 4 and 6).
Because of the sensitive nature of the data col-
lected for this study, requests to access the data set 
from qualified researchers trained in human subject 
confidentiality protocols may be sent to the Findata at 
http://finda ta.fi/en.
Statistical Analysis
Differences between study groups were analyzed 
with t test, Jonckheere- Terpstra test, and chi- square 
test. Effect sizes in baseline characteristics between 
groups were evaluated with standardized mean dif-
ference. Propensity scores based on age, alcohol 
abuse, anemia, atrial fibrillation, cerebrovascular 
disease, chronic pulmonary disease, coagulopa-
thy, dementia, depression, heart failure, hyperten-
sion, hypothyroidism, insulin- dependent diabetes, 
liver disease, malignancy, noninsulin dependent 
diabetes, paralysis, peripheral vascular disease, 
prior coronary artery bypass grafting, psychotic 
disorder, rheumatic disease, renal failure, valvular 
disease, revascularization by percutaneous coro-
nary intervention or coronary artery bypass graft-
ing, type of MI, use of cardiovascular medications 
after MI (adenosine diphosphate (ADP) receptor 
inhibitors, anticoagulants, angiotensin- converting 
enzyme inhibitors/angiotensin II receptor block-
ers, aldosterone antagonists, antiarrhythmics, beta 
blockers, ezetimibe, and statins), treating hospital, 
and study year for female sex were created with 
logistic regressions. The inverse probability weight 
was calculated using a propensity score, and IPW 
was stabilized (mean 1.00; SD 0.48). Weighting 
resulted in balanced study groups with 0.003 
standardized mean difference of propensity score 
(Table 1). Separate IPW balancing without post- MI 
medications in the propensity score was performed 
to study medication use. Subgroup analyses with 
separate propensity scoring and IPW balancing 
were performed for revascularized and nonrevas-
cularized patients and for patients aged 70 to 79 
and ≥80 years. Patient features and used medica-
tions were balanced in all subgroups (standardized 
mean difference ≤0.011 for all variables). The ex-
tent of unmeasured confounding was estimated by 
the E- value.19 The Kaplan– Meier method and Cox 
regression were used to analyze time- dependent 
outcomes. Median follow- up was 4.8 (interquartile 
range 2.3– 7.5) years. Mean follow- up was 5.1 years 
in men and 4.9  years in women. Cause- specific 
hazard models were applied in outcome analyses.20 
Proportional hazard assumptions were confirmed 
by Schoenfeld residuals. Logistic regression was 
used for the analysis of medication use. All analyses 
of balanced cohorts were weighted with stabilized 
IPW. In addition, multivariable Cox models adjusted 
with the same variables that were used for propen-
sity scoring were analyzed. Results are given as the 
mean, percentage, hazard ratio (HR), or odds ratio 
with 95% CI or ±SD. Statistical significance was in-
ferred at P value <0.05. Analyses were performed 




In the unadjusted cohort, men were younger and 
had chronic pulmonary disease, malignancies, pe-
ripheral vascular disease, history of coronary artery 
bypass grafting or MI, and ST- segment– elevation at 
presentation more often, and were more frequently 
revascularized, than women (Table  S3). Atrial fibril-
lation, heart failure, hypertension, hypothyroidism, 
dementia, psychiatric, and rheumatic diseases were 
more common among women in the unadjusted co-
hort. Nonadjusted cumulative incidence of MACE, 




Differences in baseline features and the use of post-
 MI medications were equalized with IPW adjustments, 
resulting in a balanced study population of 16 083 men 
and 15 495 men with a median age of 79 years (Table 1). 
MACE occurred in 8508 men and 7620 women in the 
IPW cohort during the follow- up period (Figure 1). The 
cumulative incidence of MACE was 18.6% in men ver-
sus 15.8% in women after 1- year follow- up (P<0.0001), 
47.0% versus 41.9% after 5- year follow- up (P<0.0001), 
and 67.7% versus 62.0% at the end of 10- year follow-
 up (HR, 1.17; CI, 1.13– 1.21; P<0.0001). The E- value was 
1.62 (CI, 1.51– 1.71). Multivariable adjusted HRs in the 
unadjusted cohort were comparable to IPW- adjusted 
results (Table S4).
Secondary Outcomes
A new MI occurred in 4059 men and 3617 women 
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Table 1. Baseline Features of Inverse Probability Weighted Older Men and Women With Myocardial Infarction
Variable
Men Women
P value |SMD|n=16 083 n=15 495
Age, y (SD) 79.3 (6.1) 79.3 (6.1) 0.858 0.002
Comorbidities
Alcohol abuse 1.2% 1.1% 0.898 0.001
Anemia 5.0% 4.9% 0.849 0.002
Atrial fibrillation 22.1% 22.4% 0.619 0.006
Cerebrovascular disease 14.9% 14.8% 0.875 0.002
Chronic pulmonary disease 15.5% 15.7% 0.655 0.005
Coagulopathy 0.4% 0.4% 0.642 0.005
Dementia 8.5% 8.3% 0.648 0.005
Depression 10.7% 10.7% 0.942 0.001
Diabetes 27.5% 27.5% 0.883 0.002
Insulin dependent 9.0% 9.2% 0.707 0.004
Noninsulin dependent 18.4% 18.4% 0.913 0.001
Heart failure 30.6% 30.7% 0.919 0.001
Hypertension 57.6% 57.8% 0.715 0.004
Hypothyroidism 5.9% 5.9% 0.977 0.0003
Liver disease 0.7% 0.8% 0.667 0.005
Malignancy 15.9% 16.2% 0.429 0.009
Metastatic tumor 0.3% 0.3% 0.887 0.002
Paralysis 0.4% 0.4% 0.975 0.0003
Peripheral vascular disease 9.3% 9.3% 0.928 0.001
Prior CABG 4.4% 4.4% 0.841 0.002
Prior MI 22.9% 23.0% 0.893 0.002
Psychotic disorder 2.9% 2.9% 0.815 0.003
Rheumatic disease 7.3% 7.3% 0.865 0.002
Renal failure 4.2% 4.1% 0.624 0.006
Valvular disease 7.4% 7.4% 0.906 0.001
Revascularization 42.7% 42.3% 0.534 0.001
Percutaneous coronary intervention 36.4% 36.1% 0.627 0.005
CABG 6.8% 6.8% 0.754 0.004
ST- segment– elevation MI 29.1% 29.2% 0.948 0.001
Anterior* 53.2% 52.9% 0.819 0.005
Post- MI medication
ADP inhibitor 53.8% 53.9% 0.935 0.001
Prasugrel or ticagrelor† 6.8% 6.5% 0.530 0.002
Anticoagulant 17.3% 17.4% 0.906 0.001
Direct oral anticoagulant ‡ 0.9% 0.6% 0.136 0.039
Angiotensin- converting- enzyme inhibitor 
or angiotensin receptor blocker
63.2% 63.3% 0.953 0.001
Aldosterone antagonist 4.5% 4.4% 0.770 0.003
Antiarrhythmic 1.3% 1.4% 0.640 0.005
Beta blocker 81.9% 81.9% 0.874 0.002
Ezetimibe 1.5% 1.5% 0.943 0.001
Statin 73.2% 73.3% 0.930 0.001
High- dose statin§ 10.6% 10.6% 0.976 0.0004
Treating hospital (n=20) 0.234 0.003
Admission year 0.816 0.003
ADP indicates adenosine diphosphate; CABG, coronary artery bypass grafting surgery; MI, myocardial infarction; and SMD, standardized mean difference.
* Of patients with ST- segment– elevation MI.
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10.5% in men versus 9.1% in women within the 1- year 
follow- up period (P=0.0003). At 10 years, the cumula-
tive incidence of new MI was 37.0% in men and 33.1% 
in women (HR, 1.16; CI, 1.11– 1.21; P<0.0001). During 
the follow- up period, 1874 men and 1783 women 
had an ischemic stroke, with cumulative incidence 
of 3.7% in men versus 3.2% in women (P=0.045) at 
1 year and 21.1% versus 19.5% at 10 years (HR, 1.10; 
CI, 1.03– 1.18; P=0.004) (Figure 2). Deaths due to car-
diovascular causes occurred in 6596 men and 5876 
women. The cardiovascular mortality rate was 10.6% 
in men versus 8.5% in women at 1  year (P<0.0001) 
and 56.0% versus 51.1% at 10- year follow- up (HR, 
1.18; CI, 1.13– 1.22; P<0.0001) (Figure 3). Also for sec-
ondary outcomes, multivariable adjusted HRs in the 
unadjusted cohort were comparable to IPW- adjusted 
results (Table S4).
Subgroup Analyses
Men had a higher hazard of MACE after MI in the sub-
groups of revascularized and non- revascularized pa-
tients, and in patients aged 70 to 79 and ≥80  years 
(Table 2). Differences in adjusted hazards of MACE, is-
chemic stroke, and cardiovascular death were similar in 
the revascularized and nonrevascularized patients and in 
both age groups. A new MI was more frequent in non- 
revascularized men compared with nonrevascularized 
women, but no sex difference was detected in revascu-
larized patients (Table 2).
Use of Secondary Preventive Medications
The use of evidence- based medication after MI dif-
fered between sexes after IPW adjustment for baseline 
features including age, multiple comorbidities, revascu-
larization, and MI type (Table 3). ADP receptor inhibitors, 
anticoagulants, and statins were used more frequently by 
men. Furthermore, when used, statins were more often 
at high dosages in men (Table 3). Beta blockers, renin- 
angiotensin- aldosterone system inhibiting medications, 
and ezetimibe were used more frequently by women 
(Table 3). Sex differences in ADP receptor inhibitor use 
were present in nonrevascularized patients with MI (35.1% 
in men versus 31.6% in women) but not in revascularized 
patients (81.7% versus 81.6%, respectively) (Table  S5). 
Women were more likely to use angiotensin- converting 
enzyme inhibitors/angiotensin II receptor blockers, beta 
blockers, and ezetimibe, regardless of revascularization 
status. There was no sex difference in statin use (88.6% 
Figure 1. Adjusted cumulative incidence of major adverse cardiovascular events in older 
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Figure 2. Adjusted cumulative incidence of new myocardial infarction (A) and 
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in both sexes) and the proportion of high- dose statin 
users in the subgroup of revascularized patients.
DISCUSSION
Focusing on adults aged ≥70  years, this IPW study 
investigated sex differences in long- term outcomes 
following admission for MI in a nationwide Finnish set-
ting. Older men were found to have 1.2- fold hazard 
of 10- year MACE, compared with older women, after 
equalizing differences in baseline features, including 
secondary preventive medications, comorbidities, MI 
type, and revascularization. Worse long- term prog-
noses in men were apparent in subgroups aged 70 
to 79 and ≥80 years, as well as in revascularized and 
nonrevascularized patients. Our findings were consist-
ent across our secondary outcomes, which comprised 
cardiovascular death, new MI, and ischemic stroke.
Despite the high burden of coronary heart disease 
in older adults, evidence to guide decision- making in 
older patients with MI is sparse.13 Means for risk stratifi-
cation applicable to older adults are needed to identify 
those patients most likely to benefit from interventions 
and more aggressive secondary prevention.21 Previous 
studies have suggested that, while younger women 
may have impaired short- term prognoses after MI com-
pared with younger men, this sex difference disappears 
or even reverses in older adults.9,16 Our finding of male 
sex as a predictor of adverse long- term cardiovascular 
outcomes is well aligned with a few previous studies 
focusing on adults aged ≥70 years.6,17 A Spanish mul-
ticenter study evaluating long- term outcomes among 
680 acute coronary syndrome patients aged ≥90 years 
showed that, despite more frailty, disability, and lower 
percutaneous coronary intervention frequency, women 
had better survival after percutaneous coronary in-
tervention.17 A Swedish registry study reported lower 
1- year mortality after MI among female 28- day survi-
vors aged 75 to 84  years, compared with their male 
counterparts.9 In our previous study within the same 
register- linkage setting, 30- day and 1- year case fatality 
rates after MI were lower in women ≥70, compared with 
men, after extensive adjustments for comorbidity bur-
dens and guideline- recommended treatments.22 Now, 
we have discovered that this survival disadvantage in 
older men extends 10 years after an index MI.
In line with our results, previous studies have revealed 
a pattern of improving prognoses in women, along with 
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increasing adjustments for sex differences in age, risk 
factors, comorbidities, and treatments.9,12 A meta- 
analysis of 35 observational studies exploring sex dif-
ferences in 1- year mortality after primary percutaneous 
coronary intervention- treated ST- segment– elevation 
MI concluded that the seemingly higher mortality rate 
in women is likely to be confounded by differences in 
cardiovascular risk factors and clinical profile.2 A report 
from the SWEDEHEART register showed that, although 
women with ST- segment– elevation MI had a lower 
probability of reperfusion therapy and higher short- term 
mortality than men, long- term mortality was higher in 
men in multivariable- adjusted analyses.12 The nonad-
justed incidence of cardiovascular outcomes was also 
higher among women in our data. Adequate adjust-
ments are thus crucial in studies aiming to explore the 
independent effects of sex on cardiovascular outcomes.
Biological, social, environmental, and community 
factors may contribute to sex/gender differences in 
health. Why female sex has, in many previous stud-
ies, been a predictor of case fatality after MI, espe-
cially among younger adults, is a matter of debate. 
Although adjustments for age and comorbidities have 
attenuated sex differences, additional explanations in-
clude dissimilarities in pathophysiology and inequities 
in evidence- based treatment. The mechanisms of MI 
may differ between sexes, too, with more plaque ero-
sions, coronary spasms, and spontaneous coronary 
artery dissections, especially in younger women.3,23,24 
These differences, however, may not characterize older 
women. A study of 6022 ST- segment– elevation MI pa-
tients showed that worse prognoses among women 
were apparent only in patients with prehospital delays 
lasting more than 1 hour, suggesting that women may 
be more vulnerable to prolonged, untreated ischemia.25
Both younger and older women may receive less 
active pharmacological and invasive treatments after 
MI than their male counterparts.6,26– 28 An Austrian 
study of MI patients ≥80 years revealed a lower inten-
tion to coronary intervention among women, compared 
with men, which was not explained by differences in 
risk factors for adverse events.6 Despite this, the ben-
efit of coronary procedures was higher among older 
women.6 In line with these findings, we observed a 
Table 2. Sex- Based Outcomes in IPW- adjusted Subgroups of Revascularized and Nonrevascularized Patients and of 
Patients Aged 70 to 79 and ≥80 Years After Myocardial Infarction
Ten- year incidence
HR (95% CI) P valueMen Women
All patients
Major adverse cardiovascular event 67.7% 62.0% 1.17 (1.13– 1.21) <0.0001
New myocardial infarction 37.0% 33.1% 1.16 (1.11– 1.21) <0.0001
Ischemic stroke 21.1% 19.5% 1.10 (1.03– 1.18) 0.004
Cardiovascular death 56.0% 51.1% 1.18 (1.13– 1.22) <0.0001
Revascularized patients
Major adverse cardiovascular event 52.7% 47.3% 1.15 (1.08– 1.21) <0.0001
New myocardial infarction 25.9% 23.9% 1.06 (0.97– 1.15) 0.181
Ischemic stroke 16.8% 15.0% 1.13 (1.01– 1.26) 0.027
Cardiovascular death 37.7% 33.8% 1.17 (1.09– 1.25) <0.0001
Nonrevascularized patients
Major adverse cardiovascular event 79.5% 73.4% 1.21 (1.16– 1.25) <0.0001
New myocardial infarction 47.0% 41.5% 1.23 (1.16– 1.29) <0.0001
Ischemic stroke 25.9% 24.1% 1.10 (1.01– 1.19) 0.024
Cardiovascular death 70.8% 64.5% 1.21 (1.16– 1.26) <0.0001
Age 70 to 79 y
Major adverse cardiovascular event 55.9% 49.8% 1.20 (1.14– 1.26) <0.0001
New myocardial infarction 29.4% 26.2% 1.16 (1.08– 1.24) <0.0001
Ischemic stroke 18.6% 17.3% 1.10 (1.00– 1.20) 0.0499
Cardiovascular death 40.4% 35.6% 1.23 (1.16– 1.30) <0.0001
Age ≥80 y
Major adverse cardiovascular event 85.1% 80.5% 1.18 (1.13– 1.23) <0.0001
New myocardial infarction 49.6% 45.0% 1.19 (1.12– 1.27) <0.0001
Ischemic stroke 26.1% 24.1% 1.11 (1.00– 1.23) 0.046
Cardiovascular death 80.4% 74.7% 1.17 (1.12– 1.23) <0.0001
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lower revascularization rate in older women, compared 
with men (35% versus 49% in unadjusted cohorts), but 
among revascularized and nonrevascularized patients, 
men had worse long- term outcomes. The low revas-
cularization rate among women with MI may be related 
to an increased prevalence of nonobstructive coronary 
artery disease in coronary angiography, a finding that 
is linked to better prognoses.29
Factors possibly contributing to poorer long- term 
outcomes among older men are multifold. Men with 
acute coronary syndrome often present with more 
severe atherosclerosis, obstructive lesions, necrotic 
plaques, and plaque ruptures in their coronary arter-
ies than women.3,30 We did not have data on smoking, 
which may contribute to worse long- term outcomes 
among men. These factors may have contributed to 
the 16% higher risk of reinfarction among men in our 
cohort, which was apparent in subgroups aged 70 
to 79 and ≥80, and in nonrevascularized patients. In 
general, women have a higher life expectancy and 
lower risk of sudden cardiac death than men, which 
is likely to be reflected in the observed sex differences 
in cardiovascular mortality rates.31 Hypothetical bi-
ological explanations for this survival gap include an 
asymmetric inheritance of sex chromosomes that ex-
poses males to deleterious recessive mutations in the 
X chromosome and differing hormonal profiles and re-
sponses to oxidative stress and inflammatory stimuli.32
In older adults, frailty is a strong predictor of mortality 
and associated with impaired outcomes after MI.33,34 An 
interesting phenomenon linked to sex, frailty, and sur-
vival is the “male– female health- survival paradox,” which 
refers to the inverse association of older women expe-
riencing more multimorbidity and frailty but living longer 
than men.35 Even though we accounted for a wide range 
of comorbidities associated with frailty, it may be consid-
ered a potential confounder in our analyses.
The sex differences in the secondary preventive 
medications noted in our study deserve some attention. 
Although differences were small, older women were 
dispensed angiotensin- converting enzyme inhibitors or 
angiotensin II receptor blockers, beta blockers, aldo-
sterone antagonists, and ezetimibe slightly more often 
than older men were. Conversely, men were more often 
dispensed ADP receptor inhibitors, anticoagulants, 
and statins. This difference was also apparent in high- 
intensity statin treatment. Among older populations, the 
benefits of statin use are well established in secondary 
prevention36 and may be associated with lower mortality 
rates also in primary prevention.37 Interestingly, following 
high- intensity statin treatment, coronary atheroma re-
gression measured by intravascular ultrasound may be 
more pronounced among women than men.38 Overall, 
although statins are the cornerstone of MI secondary 
prevention, the proportion of patients with a dispensed 
statin prescription was rather low in both sexes (72%– 
74%), warranting special attention to post- MI pharma-
cotherapy in older adults. Usage of new ADP receptor 
inhibitors and direct oral anticoagulants was low during 
our study period and there were no sex- dependent dif-
ferences in their appliance. Potential sex differences in 
prasugrel or ticagrelor and direct oral anticoagulants 
usage later in the transition phase to these new more 
potent therapies remains to be studied. Poor adher-
ence to secondary preventive medications has been 
associated with female sex in both younger and older 
patients and especially after non- ST- segment– elevation 
MI.39 Because we described the frequency of drugs dis-
pensed from pharmacies within the maximum length of 
1 reimbursement period (90 days) after discharge, our 
Table 3. Adjusted Use of Cardiovascular Prescription Medication After Myocardial Infarction, by Sex, in Older Patients
Men Women
OR (95% CI) P valuen=16 085 n=15 489
ADP inhibitor 55.0% 52.7% 1.10 (1.05– 1.15) <0.0001
Prasugrel or ticagrelor* 6.7% 6.7% 1.00 (0.87– 1.13) 0.998
Anticoagulant 17.7% 16.9% 1.10 (1.05– 1.15) <0.0001
Direct oral anticoagulant† 0.5% 0.9% 0.61 (0.32– 1.17) 0.139
Angiotensin- converting- enzyme inhibitor or 
angiotensin receptor blocker
61.9% 64.7% 0.89 (0.85– 0.93) <0.0001
Aldosterone antagonist 4.1% 4.8% 0.86 (0.77– 0.95) 0.005
Antiarrhythmic 1.4% 1.3% 1.05 (0.86– 1.27) 0.642
Beta- blocker 80.7% 83.1% 0.85 (0.81– 0.90) <0.0001
Ezetimibe 1.2% 1.9% 0.60 (0.50– 0.72) <0.0001
Statin 73.8% 72.7% 1.06 (1.01– 1.11) 0.029
High- dose statin‡ 11.0% 10.0% 1.10 (1.02– 1.20) 0.021
ADP indicates adenosine diphosphate; and OR, odds ratio.
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findings reflect the early usage of secondary preventive 
medications after MI rather than long- term adherence. 
Of note, unlike all other cardiovascular medications, as-
pirin is available over the counter without prescription in 
Finland and was therefore not included in our analyses.
The strengths of the study deserve brief discussion. 
We used a combination of previously validated, nation-
wide registries to avoid selection bias and adjusted 
the results with a broad coverage of confounders.40 
Propensity scoring and IPW are valuable tools for con-
trolling confounding factors in observational studies.41 
Residual confounding by factors not recognized in the 
national health registries is nevertheless possible and 
may influence the results of the study. We lacked more 
detailed information on laboratory measures, imaging, 
socioeconomic status, lifestyle, and functional impair-
ment. Based on the E- value, the observed HR of 1.17 
could be explained by an unmeasured confounder that 
was associated with sex and MACE by a risk ratio of 
1.6- fold each, above and beyond the measured con-
founders, but weaker confounding could not do so.19 
We did not have data on the race or ethnic backgrounds 
of study subjects, but because the Finnish population is 
predominantly White, the generalizability of our results 
to more diverse populations may be limited. An inherent 
limitation to administrative registries is that of coding er-
rors. However, it is likely that these errors happen at a 
similar rate in both sexes, and thus it is unlikely that they 
would significantly affect our main findings.
CONCLUSIONS
In conclusion, after adjustments for a broad spectrum 
of confounding factors including age, baseline comor-
bidities, and treatment of MI, older men had worse 
long- term cardiovascular prognoses after MI compared 
with older women. Our results highlight the importance 
of comprehensive adjustments for confounding fac-
tors when studying sex differences in cardiovascular 
outcomes. Although we recognize that women of all 
ages may receive fewer evidence- based treatments 
after an MI than men, our findings indicate that, when 
no dissimilarities in risk factors, comorbidities, clinical 
presentation, and treatment of MI exist, male sex is 
an independent negative prognostic factor after MI in 
older adults. Based on our findings, we believe that, in 
addition to emphasizing intention to coronary proce-
dures and intensive pharmacological secondary pre-
vention on the same grounds in both sexes, older men 
may deserve special attention after MI because of their 
worse long- term cardiovascular prognoses.
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Following nationwide, mandated-by law registry data were collected and combined from all study 
patients: 
- All hospital and emergency room admissions (International Classification of Diagnosis / ICD-
10) and operational codes (Nordic Classification of Surgical Procedures) collected from the
CRHC registry obtained from the National Institute for Health and Welfare of Finland.  
- Cancer data from the Finnish Cancer Registry obtained from the National Institute for Health
and Welfare of Finland.
- Drug purchases including Anatomical Therapeutic Chemical (ATC)-codes and purchase dates
obtained from the Social Insurance Institution of Finland.
- Drug purchase reimbursement permissions including permission codes and underlying ICD
diagnoses obtained from the Social Insurance Institution of Finland.
- Mortality data including date and causes of death obtained from the Statistics Finland.
Outcomes 
The primary outcome of interest was composite major adverse cardiovascular event. Secondary 
outcomes were new myocardial infarction, ischemic stroke, and cardiovascular death. Follow-up 
started from 90 days after MI and ended at 10-years later. Follow-up data was available to Dec 31st 
2018.  
Definitions: 
- Major adverse cardiovascular event: New myocardial infarction, ischemic stroke, and
cardiovascular death.
- New myocardial infarction: ICD-10 code I21* or I22* as primary diagnosis in new hospital
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- Ischemic stroke: ICD-10 code I63* as diagnosis in new hospital admission or as any cause of 
death.
- Cardiovascular death: Death with ICD-10 code I* as the underlying cause of death.
- Usage of prescription drug after myocardial infarction: Drug purchase within 90 days after 
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ICD-10 codes Prescription drug 
reimbursement codes 
Operational codes 
Alcohol abuse F10, E52, G62.1, I42.6, K29.2, 
K70.0, K70.3, K70.9, T51, Z50.2, 
Z71.4, Z72.1  
309 
Anemia (history of) D50.0, D50.8, D50.9, D51-D53 107, 122,175, 376 
Atrial fibrillation I48 342, 351 
Cerebrovascular disease G45, G46, H34.0, I60–I69 
Chronic pulmonary disease I27.8, I27.9, J40–J47, J60–J67, 
J68.4, J70.1, J70.3 
203, 210, 284, 304, 348, 356 
Coagulopathy D65–D68, D69.1, D69.3– D69.6 126, 161, 172, 194, 332, 357, 375 
Dementia A81.0, F00–F03, F05.1, G30, G31 307 
Depression* F20.4, F31.3–F31.5, F32, F33, 
F34.1, F41.2, F43.2 
Diabetes E10-E14 103, 215, 160, 162, 358, 171, 177, 
285, 346, 371, 382 
Heart failure I09.9, I11.0, I13.0, I13.2, I25.5, 
I42.0, I42.5–I42.9, I43, I50, P29.0 
201, 283, 354, 381 
Hypertension I10-I13, I15 205 
Hypothyroidism E00-E03, E89.0 104 
Liver disease B18, I85, I86.4, I98.2, K70, K71.1, 
K71.3– K71.5, K71.7, K72– K74, 
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Malignancy (history of) C 115, 116, 128, 130, 155, 156, 158, 
159, 163, 167, 168, 169, 173, 176, 
180, 184, 185, 189, 191, 192, 197, 
198, 302, 311, 312, 322, 323, 324, 
325, 328, 329, 337, 340, 341, 343, 
352, 360, 361, 362, 363, 369, 372, 
373, 378 
Paralysis G04.1, G11.4, G80.1, G80.2, G81, 
G82, G83.0–G83.4, G83.9 
Peripheral vascular disease I70, I71, I73.1, I73.8, I73.9, I77.1, 
I79.0, I79.2, K55.1, K55.8, K55.9, 
Z95.8, Z95.9 
Prior CABG Z951 FNA, FNB, FNC, FND, FNE** 
Prior myocardial infarction I21**, I22, I25.2  
Psychotic disorder F20, F21–F25, F28, F29, F30.2, 
F31.2, F31.5 
112, 188 
Rheumatic disease L94.0, L94.1, L94.3, M05, M06, 
M08, M12.0, M12.3, M30, 
M31.0– M31.3, M32–M35, M45, 
M46.0, M46.1, M46.4, M46.8, 
M46.9 
202, 281 
Renal failure I120, I13.0, N18, N19, N25.0, 
Z49.0– Z49.2, Z94.0, Z99.2 
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Valvular disease A52.0, I05–I08, I09.1, I09.8, I34–
I39, Q23.0–Q23.3, Z95.2– Z95.4 
Revascularization 
PCI FN2AA, FN2AB, FN2BA, 
FN2CA, FN2CB, FN2CC, 
FN2CD, FN2CE, FN2CT, 
FN2DA, FN2DB, FN2EA, 
FN1AT, FN1BT, FN1YT, 
FNG00, FNG10, FN2DA, 
TFN40, TFN50, TFN10, FN2EF, 
FN2EB, FN2EC, FN1ST 
CABG FNA, FNB, FNC, FND, FNE 
ST-elevation MI I21.0-21.3 
Anterior I21.0 
* Or purchase of antidepressant medication within 90 days prior to MI. ** Before index MI admission.
Table S1. Definitions for co-morbidities and patient baseline features. International Classification of Diseases (ICD) coding algorithms adopted with minor 




 http://ahajournals.org by on D
ecem
ber 29, 2021
Table S2. Anatomical Therapeutic Chemical Classification (ATC) codes for studied prescription 
drugs. ADP = adenosine diphosphate, ACEi = Angiotensin-converting-enzyme inhibitor, ARB = 
angiotensin receptor blocker. High intensity statin therapy was defined as in ≥40 mg of atorvastatin, 
≥20 mg of rosuvastatin, or 80 mg of simvastatin per day. 
ATC-codes 
ADP-inhibitor B01AC04, B01AC05, B01AC22, B01AC24 
Anticoagulant B01AA, B01AE, B01AF, B01AX06 
Antidepressant N06A, N06CA 
Antidiabetic A10 
Insulin A10A 
 Non-insulin A10B 
ACEi or ARB C09, C10BX04, C10BX06, C10BX07, C10BX10, C10BX11, 
C10BX12, C10BX13, C10BX14, C10BX15 
Aldosterone antagonist C03DA01, C03DA04 
Antiarrhythmic  C01B 
Beta-blocker C07, C09BB, C09DA, C09BX02, C09DX05 
Ezetimibe C10AX09, C10BA02, C10BA05, C10BA06 








Variable  n=16152 n=15408 P-value |SMD|
Age, years (SD) 78.0 (5.7) 80.8 (6.2) <0.0001 0.470 
Co-morbidities 
Alcohol abuse 1.8% 0.5% <0.0001 0.119 
Anemia 4.3% 5.6% <0.0001 0.060 
Atrial fibrillation 21.5% 23.4% <0.0001 0.046 
Cerebrovascular disease 15.0% 14.8% 0.607 0.006 
Chronic pulmonary disease 16.2% 14.3% <0.0001 0.053 
Coagulopathy 0.3% 0.4% 0.364 0.010 
Dementia 6.8% 9.9% <0.0001 0.112 
Depression 7.9% 13.6% <0.0001 0.184 
Diabetes 27.1% 27.8% 0.211 0.014 
Insulin dependent 8.9% 9.1% 0.468 0.008 
 Non-insulin dependent 18.3% 18.7% 0.365 0.010 
Heart failure 26.7% 35.4% <0.0001 0.189 
Hypertension 52.4% 63.9% <0.0001 0.234 
Hypothyroidism 2.5% 9.6% <0.0001 0.300 
Liver disease 0.7% 0.7% 0.828 0.002 
Malignancy  19.2% 11.8% <0.0001 0.203 
Metastatic tumor 0.3% 0.2% 0.043 0.023 
Paralysis 0.3% 0.4% 0.362 0.010 
Peripheral vascular disease 10.4% 7.9% <0.0001 0.087 
Prior CABG 5.9% 2.8% <0.0001 0.153 
Prior MI 24.3% 21.1% <0.0001 0.077 
Psychotic disorder 2.2% 3.7% <0.0001 0.093 
Rheumatic disease 5.6% 9.3% <0.0001 0.141 
Renal failure 4.9% 3.3% <0.0001 0.081 
Valvular disease 6.6% 8.3% <0.0001 0.066 
Revascularization 49.3% 34.8% <0.0001 0.298 
PCI 41.0% 30.8% <0.0001 0.214 
 CABG 8.9% 4.3% <0.0001 0.187 
ST-elevation MI 30.9% 27.6% <0.0001 0.074 
Anterior* 52.1% 55.0% 0.007 0.056 
Post-MI medication 
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 Prasugrel or ticagrelor ** 7.2% 5.6% <0.0001 0.065 
Anticoagulant 18.0% 16.8% 0.003 0.034 
 DOAC*** 0.6% 0.7% 0.596 0.014 
ACEi or ARB 63.1% 63.9% 0.174 0.015 
Aldosterone antagonist 3.9% 5.0% <0.0001 0.053 
Antiarrhythmic 1.5% 1.1% 0.001 0.037 
Beta-blocker 81.9% 81.8% 0.862 0.002 
Ezetimibe 1.3% 1.5% 0.242 0.013 
Statin 77.4% 68.6% <0.0001 0.198 
 High-dose statin**** 12.0% 8.7% <0.0001 0.108 
Treating hospital (n=20) 0.0004 0.058 
Admission year <0.0001 0.087 
Table S3. Baseline features of older men and women with myocardial infarction in non-adjusted 
cohort. ACEi = Angiotensin-converting-enzyme inhibitor, ADP = adenosine diphosphate, ARB = 
angiotensin receptor blocker, CABG = Coronary artery bypass grafting surgery, MI = Myocardial 
infarction, PCI = Percutaneuos coronary intervention, SMD = Standardized mean difference. *Of ST-
elevation MI patients.  ** Of ADP-users. *** Of anticoagulant users. ****Of statin users.  Dow
nloaded from
 http://ahajournals.org by on D
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Non-adjusted incidence Univariable Multivariable 
Men Women HR (95%CI) P-value HR (95%CI) P-value 
Major adverse 
cardiovascular event  
1-year 16.5% 17.9% 0.001 <0.0001 
10-year 63.4% 67.4% 0.89 (0.86-0.92) <0.0001 1.22 (1.18-1.26) <0.0001 
New myocardial infarction 
1-year 9.1% 10.2% 0.001 <0.0001 
10-year 33.9% 36.6% 0.90 (0.86-0.94) <0.0001 1.20 (1.14-1.26) <0.0001 
Ischemic stroke 
1-year 3.5% 3.5% 0.999 0.028 
10-year 20.1% 20.9% 0.95 (0.89-1.01) 0.112 1.13 (1.06-1.22) 0.0004 
Cardiovascular death 
1-year 9.1% 10.2% 0.001 <0.0001 
10-year 50.8% 57.4% 0.83 (0.80-0.86) <0.0001 1.25 (1.20-1.29) <0.0001 
Table S4. Non-adjusted sex-based cumulative incidence of outcomes at 1-year and 10-years. Results of unadjusted and multivariable adjusted 
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Revascularized patients Non-revascularized patients 
Men Women Men Women 
N=7976 N=5380 OR (95%CI) P-value N=8129 N=10103 OR (95%CI) P-value
ADP-inhibitor 81.7% 81.6% 1.00 (0.92-1.10) 0.925 35.1% 31.6% 1.17 (1.10-1.25) <0.0001 
 Prasugrel or ticagrelor * 8.7% 8.7% 0.99 (0.87-1.14) 0.895 3.1% 2.7% 1.19 (0.88-1.61) 0.270 
Anticoagulant 17.2% 15.8% 1.11 (1.01-1.22) 0.029 18.1% 17.8% 1.02 (0.94-1.10) 0.648 
 DOAC** 0.3% 0.9% 0.36 (0.11-1.12) 0.078 0.7% 0.8% 0.82 (0.36-1.88) 0.646 
ACEi or ARB 69.7% 72.6% 0.87 (0.80-0.94) 0.0003 56.1% 59.0% 0.89 (0.84-0.94) <0.0001 
Aldosterone antagonist 3.9% 4.8% 0.81 (0.68-0.96) 0.014 4.3% 4.8% 0.89 (0.77-1.03) 0.106 
Antiarrhythmic 1.5% 1.8% 0.93 (0.63-1.09) 0.174 1.3% 0.9% 1.37 (1.03-1.81) 0.029 
Beta-blocker 85.7% 88.5% 0.78 (0.70-0.86) <0.0001 76.9% 79.0% 0.88 (0.82-0.95) 0.001 
Ezetimibe 1.5% 2.8% 0.54 (0.42-0.68) <0.0001 0.9% 1.3% 0.71 (0.54-0.95) 0.019 
Statin 88.6% 88.6% 0.99 (0.89-1.11) 0.907 62.6% 61.0% 1.07 (1.01-1.14) 0.020 
High-dose statin*** 13.8% 12.8% 1.09 (0.98-1.21) 0.131 8.1% 7.2% 1.14 (0.99-1.32) 0.061 
Table S5. Usage of cardiovascular prescription medication after myocardial infarction by sex in inverse probability weighted subgroups of 
revascularized and non-revascularized patients. ACEi = Angiotensin-converting-enzyme inhibitor, ARB = angiotensin receptor blocker, 
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